Physician profile
Ting Wu
NPI 1730594243
$9,353.52
in general payments reported to CMS, 2019-2025
43 companies · $4,372 in 2025
The $4,372 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.06 · 2023: $652 · 2024: $4,288 · 2025: $4,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,312.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,098.89 | 2023-2025 | Botox |
| Pfizer INC. | $802.29 | 2023-2025 | |
| Ucb, INC. | $658.50 | 2023-2025 | Briviact, Rystiggo, Zilbrysq |
| Biogen, INC. | $515.59 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Eisai INC. | $507.07 | 2023-2025 | |
| Lilly USA, LLC | $395.86 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Amneal Pharmaceuticals LLC | $395.82 | 2024-2025 | Crexont, Rytary, Ongentys |
| Otsuka America Pharmaceutical, INC. | $362.87 | 2023-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $343.81 | 2024-2025 | Nuplazid |
| Lundbeck LLC | $321.43 | 2024-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $262.49 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Sk Life Science, INC. | $230.90 | 2023-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $202.19 | 2023-2025 | Ultomiris |
| Celgene Corporation | $188.86 | 2023-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $162.34 | 2023-2025 | Ingrezza |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $161.36 | 2024-2025 | Mavenclad |
| Argenx US, INC. | $151.27 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Boston Scientific Corporation | $144.25 | 2024-2025 | General - Therapies, General - Pain Management |
| Merz Pharmaceuticals, LLC | $131.62 | 2025 | Xeomin, Inbrija |
| Novartis Pharmaceuticals Corporation | $127.12 | 2023-2025 | |
| Kyowa Kirin, INC. | $124.72 | 2023-2024 | Nourianz |
| Axsome Therapeutics, INC. | $116.54 | 2025 | Symbravo |
| Genentech USA, INC. | $105.13 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $94.46 | 2024 | |
| Vanda Pharmaceuticals INC. | $87.63 | 2024-2025 | Ponvory |
| Astrazeneca Pharmaceuticals Lp | $77.78 | 2024-2025 | Wainua |
| Mdd US Operations, LLC | $62.53 | 2023-2024 | Apokyn, Gocovri, Gocovri |
| Insightec,INC | $58.22 | 2024-2025 | Exablate |
| Alnylam Pharmaceuticals INC. | $52.96 | 2024 | Onpattro |
| Genzyme Corporation | $48.58 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $42.27 | 2025 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $34.75 | 2023 | |
| Neurelis, INC. | $33.83 | 2025 | Valtoco |
| Ipsen Biopharmaceuticals, INC | $33.13 | 2024 | Dysport |
| Life Molecular Imaging Ltd | $31.71 | 2024 | Neuraceq |
| Azurity Pharmaceuticals, INC. | $28.70 | 2025 | Horizant |
| Livanova USA, INC. | $27.58 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Catalyst Pharmaceuticals, INC. | $26.41 | 2024 | |
| Tanabe Pharma America, INC. | $22.77 | 2024 | |
| Amylyx Pharmaceuticals, INC. | $22.46 | 2024 | Relyvrio |
| Cycle Pharmaceuticals INC | $20.87 | 2025 | Tascenso Odt, Bafiertam |
| Sumitomo Pharma America, INC. | $19.94 | 2024 | Aptiom |
| Neuropace, INC. | $16.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ting Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.